Khedr Mohammed Ahmed, El-Araby Hanaa Ahmed, Konsowa Hatem Abdel-Sattar, Sokar Samia Salem, Mahmoud Mohammed Fathy, Adawy Nermin Mohammed, Zakaria Haidy Mohammed
Department of Pediatric Hepatology, Gastroenterology and Nutrition, National Liver Institute, Menoufia University, Shebin El-koom, Menoufia, Egypt.
Pharmacology and Toxicology Department, Faculty of Pharmacy, Tanta University, Egypt.
Clin Exp Hepatol. 2019 Mar;5(1):81-87. doi: 10.5114/ceh.2019.83161. Epub 2019 Feb 20.
We aimed to assess oxidative stress factors, glutathione peroxidase (GPX) and malondialdehyde (MDA) in children with chronic hepatitis C (CHC) and their relation to treatment response.
The study included 50 children with chronic hepatitis C virus (HCV) before treatment (naïve HCV), 25 children responders to HCV treatment, 25 children non-responders to HCV treatment and 25 healthy controls. All patients and controls were subjected to GPX and MDA measurement by enzyme-linked immunosorbent assay.
The average GPX activity in erythrocytes of naïve CHC patients was 29.2 ±10.3 mU/ml. It was statistically significantly lower than the average activity of GPX in erythrocytes of the healthy control group (47.3 ±5.2 mU/ml) ( < 0.05). The average GPX activity in erythrocytes of the responder group was 34.93 ±3.17 mU/ml. It was statistically significantly higher than the average activity of GPX in erythrocytes of the non-responder group (11.7 ±4.2 mU/ml) ( < 0.05). Plasma MDA was significantly higher in naïve CHC patients than in healthy controls (9.7 ±3.7 nmol/ml vs. 3 ±1.1 nmol/ml, < 0.0001). Furthermore, plasma MDA concentration was significantly decreased in the responder group (5.36 ±0.7 nmol/ml) and elevated in the non-responder group (16.05 ±2.9 nmol/ml).
Lower pretreatment levels of GPX and higher MDA level might be markers of oxidative stress occurring in HCV patients. Reversal of changes of these levels with completion of the treatment may indicate a correlation between oxidative stress and the viral pathogenesis.
我们旨在评估慢性丙型肝炎（CHC）患儿的氧化应激因子、谷胱甘肽过氧化物酶（GPX）和丙二醛（MDA），以及它们与治疗反应的关系。
该研究纳入了50例未经治疗的慢性丙型肝炎病毒（HCV）患儿（初治HCV患儿）、25例HCV治疗反应者、25例HCV治疗无反应者以及25例健康对照。所有患者和对照均通过酶联免疫吸附测定法进行GPX和MDA检测。
初治CHC患者红细胞中的平均GPX活性为29.2±10.3 mU/ml。该活性显著低于健康对照组红细胞中的平均GPX活性（47.3±5.2 mU/ml）（P<0.05）。反应者组红细胞中的平均GPX活性为34.93±3.17 mU/ml。该活性显著高于无反应者组红细胞中的平均GPX活性（11.7±4.2 mU/ml）（P<0.05）。初治CHC患者的血浆MDA显著高于健康对照（9.7±3.7 nmol/ml对3±1.1 nmol/ml，P<0.0001）。此外，反应者组的血浆MDA浓度显著降低（5.36±±0.7 nmol/ml），而无反应者组则升高（16.05±2.9 nmol/ml）。
治疗前较低的GPX水平和较高的MDA水平可能是HCV患者发生氧化应激的标志物。治疗完成后这些水平变化的逆转可能表明氧化应激与病毒发病机制之间存在关联。
